Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy Based on Tumor Location, Ground Glass Opacity Component and Frozen Section Diagnosis in Peripheral cT1N0M0 Invasive Non-small Cell Lung Cancer

NCT03216551 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT03216551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03216551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy Based on Tumor Location, Ground Glass Opacity Component and Frozen Section Diagnosis in Peripheral cT1N0M0 Invasive Non-small Cell Lung Cancer
Lead sponsor
Fudan University
Phase
Observational
Overall status
Completed
Start date
March 14, 2019
Completion date
May 30, 2022
Enrollment
1,076 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymph node metastases, non-small cell lung cancer stage i